The Gary Null Show - 12.07.21

Long-term persistence of the SARS-CoV-2 spike protein: evidence and implications
Michael Palmer, MD and Sucharit Bhakdi, MD, 27th November, 2021

This paper discusses the recent study by Bansal et al. [1] on the detection of spike protein in persons vaccinated with the Pfizer mRNA vaccine. The most significant finding is that spike protein is found on exosomes, that is, cell-derived vesicles, for at least four months after the second injection. This surprisingly long persistence raises the prospect of sustained inflammation within and damage to organs which express the spike protein. Conclusions • Long-lasting persistence of spike protein • Delayed onset of spike protein expression—but observation limited to spike on exosomes • EMA report on Pfizer also reported relatively slow onset of spike expression; on the other hand, early onset of blood clots etc. suggests early onset of spike expression While some specific claims made by this paper can be debated, the very long-lasting persistence of the spike protein in the body is convincingly demonstrated. Whether it is the mRNA encoding the spike protein that persists or rather the spike protein itself remains to be determined. Nevertheless, as long as the spike protein appears on either exosomes or apoptotic vesicles, it must be present on cell membranes; and as long as it is found there, the immune system will attack those cells. Protracted inflammation and impaired organ function have been reported both with the virus infection itself [7] and after vaccination [8]. While inflammation may arise from autoimmunity downstream of intense acute tissue damage, the long-term persistence of spike protein after vaccination offers another straightforward explanation, and it supports the notion that the vaccines will give rise to lingering and slowly progressing inflammatory disease. We must also note that the spike protein persists for at least twice as long as the participants of Pfizer’s farcical and fraudulent [9, 10] ‘clinical trials’ were observed, on average, after the second vaccination [11]. It follows that the reports on side effects which occurred in those trials cannot possibly be complete.